Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy driven by the BCR-ABL fusion tyrosine kinase. The central role played by BCR-ABL1 in the pathogenesis of CML facilitated the development of the tyrosine kinase inhibitor (TKI) imatinib mesylate, the first actual targeted therapy in cancer history. Imatinib competes with ATP at the active site of BCR-ABL1 kinase. Despite outstanding clinical results, imatinib as well as other BCR-ABL1 TKIs have been associated with limited rates of complete molecular response and the development of mutations within the kinase domain of BCR-ABL1 that impairs TKI binding. To override such drawbacks, an array of novel non-ATP-competitive therapies with distinct mechanisms of action is undergoing preclinical, and in some cases, early clinical stages of development. This review focuses on the most promising among such therapeutics.
Introduction
Several experimental models have demonstrated that BCR-ABL1 is central to the pathogenesis of chronic myelogenous leukemia (CML) and that its protein product, the BCR-ABL1 kinase, plays a pivotal role in the development and maintenance of BCR-ABL1-mediated leukemogenesis in vivo. 1 This provided the rationale for the targeted use of tyrosine kinase inhibitors (TKI) that bind to the canonical ATP-binding pocket of the BCR-ABL kinase. One such TKI, imatinib mesylate, inhibits BCR-ABL1 kinase with 50% inhibitory concentration (IC 50 ) values ranging between 0.1 and 0.5 mM. [2] [3] [4] In newly diagnosed patients with CML in chronic phase (CP), imatinib therapy results in complete hematologic and cytogenetic (CCyR) response rates of 98 and 87%, respectively after 5 years of follow-up. 5 However, a significant proportion of patients receiving imatinib therapy develop resistance to imatinib, mainly owing to point mutations within the kinase domain of the BCR-ABL1 enzyme. These mutations impair imatinib binding by either interfering directly with the ability of imatinib to access the kinase domain (for example, T315I) or by distorting the ABL1 kinase/imatinib interface, which precludes BCR-ABL1 from achieving the inactive conformation required for imatinib binding (for example, A-loop mutations). Notably, the most frequent mutations are those that map to the P-loop region of the kinase domain, which serves as a docking site for phosphate moieties of ATP. 6, 7 The frequency of BCR-ABL1 mutations in patients resistant to imatinib ranges from 40 to 90%. [7] [8] [9] [10] [11] [12] To date, more than 50 different ABL kinase point mutations have been detected in patients with imatinibresistant CML. 6, 7, [13] [14] [15] Of particular concern is the development of the BCR-ABL1 T315I mutation, which affects a highly conserved 'gatekeeper' threonine residue near the ABL catalytic domain. The T315I mutation imparts total insensitivity to imatinib as well as to the second generation of ABL1 TKIs nilotinib, dasatinib and bosutinib ( Figure 1) . [16] [17] [18] [19] [20] In addition to the development of mutations, leukemic residual cells are detectable in most patients with CML receiving small-molecule ATP-competitive TKI therapy, 5 which has been linked to the limited activity of these agents to eradicate primitive CML hematopoietic cells. This article zeroes in on therapeutic approaches aiming at BCR-ABL1-positive leukemia cells different from standard ATP-competitive small-molecule TKIs.
Non-ATP-competitive BCR-ABL1 kinase inhibitors
While all TKIs currently in clinical use compete with ATP for the canonical binding site of the BCR-ABL1 kinase, other smallmolecule compounds have been designed to target BCR-ABL1 motifs remote from the kinase domain. In doing so, the activity of these drugs remains unaffected by the presence of mutations in the kinase domain of the enzyme (Table 1) .
GNF-2
GNF-2 is the lead compound of a series of novel 4,6-disubstituted pyrimidines developed by means of high-throughput differential cytotoxicity assays. 21 This compound represents the first of a kind whose putative mechanism of action is the inhibition of BCR-ABL1 kinase by interfering with the autoregulatory allosteric myristate cleft at the N terminus of BCR-ABL1, which stabilizes the protein in an inactive state. 21 GNF-2 inhibited the proliferation of BCR-ABL1-transformed cells (Table 1) but lacked activity against the kinase domain of BCR-ABL1 and a panel of 63 other kinases. This remarkable selectivity is believed to be a direct consequence of the association of GNF-2 with the myristate-binding pocket of BCR-ABL1. 21 A recent mutational screen coupling BCR-ABL1 mutagenesis with selection of drug resistance using GNF-2 as probe showed that 450% of all GNF-2-resistant clones harbored mutations involved the BCR-ABL1 myristate-binding pocket or the ABL1 SH3 domain, supporting two different mechanisms of mutational resistance: first, directly through disruption of GNF-2 contact sites at the myristate-binding pocket and second, indirectly through SH3 mutants that lose affinity for a BCR-ABL1 putative inhibitory binding protein. In the presence of GNF-2, ABI-2 was found to co-immunoprecipitate with BCR-ABL1 and was associated with reduced BCR-ABL1 autophosphorylation levels, supporting its role as a potential candidate inhibitory binding partner and revealing a previously undescribed indirect mechanism of BCR-ABL1 inhibition by an allosteric non-ATP inhibitor.
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ABL1 switch pocket inhibitors
A new class of small-molecule non-ATP-competitive inhibitors designed to target 'switch pockets' that regulate conformational changes involved in kinase activity has been recently reported. These agents have the ability to avoid steric clash with the gatekeeper mutant T315I at the active site of ABL kinase, inhibit ABL1 that is either unphosphorylated ('switch-off') or phosphorylated ('switch-on') at Tyr393 and have prolonged residency time on the kinase (off rate 400 versus 3 min for imatinib). 23 The lead compound DCC-2036 induces potent inhibition of proliferation and mediates apoptosis of Ba/F3 cells expressing wild-type as well as mutant BCR-ABL1 isoforms (Table 1) , without significant inhibition of parental Ba/F3 cells in IL-3 (IC 50 1415 nM). 23 Notably, DCC-2036 also inhibited potently the proliferation of BCR-ABL1 T315-expressing Ba/F3 cells (IC 50 7.9 nM). In Balb/c mice injected with Ba/F3-BCR-ABL1 T315I cells, DCC-2036 daily dosing prolonged survival and a single oral dose of 100 mg kg À1 inhibited the phosphorylation of ABL1 and signal transducer and activator of transcription 5 (STAT5) for 48 h, supporting the potential clinical use of ABL1 switch pocket inhibitors in imatinibresistant CML. 23 Despite the high activity of DCC-2036 against T315I and other resistant mutants, it must be noted that P-loop mutants exhibited relative resistance against this compound. The structural basis for this phenomenon is not yet well understood. The excellent oral bioavailability, pharmacokinetics and safety profile of DCC-2036 in preclinical studies supports its further development in clinical trials of human CML.
ON012380
ON012380 is a small-molecule 10-fold more potent than imatinib against BCR-ABL1 kinase. 24 ON012380 competes with natural substrates of BCR-ABL1 such as CrKL, but not with ATP. 24 It has been suggested that ON012380 acts through blocking the substrate-binding site of BCR-ABL1 kinase rather than the ATP-binding site, which may render the compound unaffected by mutations in the ABL tyrosine kinase domain (Table 1) . 24 Intravenous administration of ON012380 caused regression of leukemias induced by intravenous injection of 32DcI3 cells expressing BCR-ABL1 T315I in mice. 24 The safety and activity of ON012380 in clinical trials is yet to be tested.
Targeting BCR-ABL1 mRNA Given the pivotal role that BCR-ABL1 kinase plays as the main driver of the pathogenesis of CML, an alternative approach to prevent BCR-ABL1 kinase activation of downstream signaling pathways is to directly interfere with the expression of BCR-ABL1 mRNA. Antisense approaches have been widely derided as a pipe dream chiefly due to difficulties in its technical execution. However, over the last years significant insights have been gained regarding artificial gene expression and delivery of these novel therapeutics in a more stable and targeted manner. Several antisense approaches designed to specifically target BCR-ABL1 are under development.
RNA interference
BCR-ABL1 translation inhibition can be accomplished by small interfering RNA (siRNA) technology. siRNA describes a highly conserved regulatory mechanism that mediates imatinib dasatinib bosutinib nilotinib Figure 1 Chemical structure of imatinib and the second-generation tyrosine kinase inhibitors (TKIs) nilotinib, dasatinib and bosutinib. The activity of all compounds on cell proliferation of the BCR-ABL1-positive K562 is shown for comparison. IC 50 is the concentration of an inhibitor required for 50% inhibition of cell proliferation. The activity of ON012380 was tested against unmutated-and p210 BCR-ABL1 mutant-carrying 32Dcl3 cells. All values are expressed in nmol l À1 .
Experimental non-ATP-competitive therapies for CML A Quintás-Cardama sequence-specific post-transcriptional gene silencing. 25, 26 siRNAs are 20-25 nucleotide-long double-stranded RNA fragments derived from the enzymatic action of the RNase III enzyme Dicer upon double-stranded RNA. 27 Recently, the 21-nucleotide siRNAs b3a2_1 and b3a2_3 were found to induce reductions of BCR-ABL1 mRNA levels by up to 87% in peripheral blood mononuclear primary cells from patients with CML and BCR-ABL1-positive cell lines. 28 Although the reduction in the levels of mRNA expression were transient, siRNA homologous to b3a2-fusion site increased the sensitivity to imatinib in BCR-ABL1-overexpressing cells and in cell lines expressing the imatinib-resistant mutation H396P. 29 Although the activity of BCR-ABL1 fusion sequence-directed siRNA against primary CML cells has also been demonstrated by other independent groups, 30,31 the degree of suppression has not been tested for leukemogenicity in vivo.
Another powerful RNA-based antisense approach is the use of microRNAs (miRNAs). miRNAs are short, single-stranded, noncoding RNA molecules directly involved in post-transcriptional regulation of 430% protein-coding genes. An advantage of miRNAs is their ability to be expressed in tandem arrays. It has been reported that selected combinations of triple miRNA mimics directed to specific ABL1 sequences delivered by lentiviral vectors significantly suppressed the oncogenic activity of BCR-ABL1 kinase and prolonged the survival of CB17.scid/ scid mice injected with 1 Â 10 6 Ba/F3 cells expressing p210
. 32 Single, double and particularly triple miRNA-expressing constructs were superior to BCR-ABL1 junction-specific short hairpin RNA (shRNA) for suppression of BCR-ABL1 protein and phosphorytosine-modified proteins both in wild-type-and TKIresistant mutated BCR-ABL1 isoforms. 32 In order to fully exploit the potential of antisense technology directed at BCR-ABL1 mRNA, improved systems will be required to stably deliver these therapeutics efficiently into CML primary cells. The most commonly used delivery systems for siRNA transfer into primary CML cells are viral-based techniques. Adenoviruses and lentiviruses are the most effective gene transfer vehicles, rendering high transduction efficiencies. Recent advances in targeting of retroviral particles by improved engineering of surface receptor specificity may further improve siRNA delivery to primary CML cells. 33 The high transduction efficiencies obtained with viral-based methods comes at the expense of many disadvantages, mostly involving infection risks, which will undoubtedly preclude their use in clinical practice. Commonly used nonviral transfection techniques include lipofection/polyfection reagents, calcium phosphate precipitation and electroporation. However, these methodologies yield lower transduction efficiencies than viral-based techniques and are frequently associated with high cell mortality. These shortcomings have been greatly mitigated by the use of nucleofector technology, a novel nonviral transfection methodology designed to target primary cells and other hard-to-transfect cell lines. 34 Nucleofection is an electroporation-based technique that combines the use of a specific nucleofector solution and specific electrical parameters to deliver siRNA directly into the cell nucleus, therefore avoiding the use of viral particles and the need for cell division. 34 The high transduction efficiencies obtained by nucleofection and its nonviral nature might facilitate the therapeutic use of siRNA in CML.
Ribozymes
Ribozymes are metalloenzymes made entirely of RNA that incapacitate target RNA sequences by catalyzing the cleavage of the phosphodiester backbone. 35 The catalytic domain of the ribozyme consists of 12 highly conserved ribonucleotides flanked by short sequences that mediate base hybridization to complementary bases surrounding a GUX triplet in the target RNA. 35 Although hindered by methodological limitations such as the lack of adequate delivery platforms, it has been shown that BCR-ABL1 expression can be dramatically reduced in EM-2 cells by transcript-specific ribozyme. 36 The ability of ribozymes to discriminate single-nucleotide mutant RNA sequences from their wild-type counterparts may provide an invaluable means to target imatinib-resistant mutant BCR-ABL proteins.
Antisense oligonucleotides
An alternative strategy for downregulation of the expression of BCR-ABL1 is the use of antisense nucleotides encoding for short single-stranded DNA sequences complementary to target BCR-ABL1 mRNA. Once introduced in the cell, they form mRNA/ oligonucleotide heteroduplexes that prevent BCR-ABL1 mRNA from associating with ribosomes, thus facilitating their degradation by RNase H. 37 Although this system has proved successful in murine models of CML, 38 its clinical application has been hampered by poor oligonucleotide stability and by the requirement to use high doses of oligonucleotides to reach a meaningful antileukemic effect that may result in undesirable off-target toxicity due to nonspecific binding.
Peptide nucleic acids
Peptide nucleic acids (PNAs) have emerged as a promising new type of therapeutic oligonucleotides in the form of antisense and anti-gene molecules. 39 PNAs are nonionic DNA mimics that have outstanding potential for recognizing duplex DNA. 40 PNAs are hybrid molecules formed by both a peptide and a nucleic acid and consisting of N-(2-aminoethyl)glycine monomers linked by amide bonds. 40, 41 The purine (A and G) and pyrimidine (C and T) nucleobases are attached to this polyamide backbone via a methylene carbonyl linkage. 42 On the basis of these characteristics, PNAs are considered as synthetic DNA analogues that are resistant to nucleases and proteases and have the ability to bind with very high affinity to RNA. For this reason, PNAs are very attractive therapeutic tools for the treatment of malignancies, aiming at reducing the expression of oncogenes in vivo. In a recent report, BCR-ABL1-positive KYO-1 cells were treated with a 13mer PNA sequence (asPNA), which was designed to hybridize to the b2a2 junction of BCR-ABL1 mRNA. The cellular uptake of asPNA was enhanced by covalently linked the latter to the basic peptide VKRKKKP (NLS-asPNA). 42 KYO-1 cells treated with NLS-asPNA had a remarkable reduction in the level of b2a2 mRNA as well as p210 BCR-ABL protein kinase, which resulted in inhibition of cell proliferation to 50 ± 5% of the control and inhibited completion of the cell cycle. 42 Immune strategies against CML CML is regarded as a paradigmatic example of a malignancy responsive to immune manipulations. 43, 44 Several lines of evidence support the contention that immune-mediated events play an important role in the suppression of the CML clone. First, a subset of patients who received interferon-a (IFN-a) therapy have maintained a durable hematologic and cytogenetic responses after treatment discontinuation. 45 Second, patients who relapse after allogeneic stem cell transplantation (SCT) can Experimental non-ATP-competitive therapies for CML A Quintás-Cardama be effectively rescued with donor lymphocyte infusions due to a graft-versus-leukemia effect. 46 Based on these observations, several immune strategies have been developed for the treatment of CML.
Vaccines for CML
Several vaccines have been shown to elicit immune responses against tumor antigens whose expression is differentially expressed in CML cells. One such antigen, proteinase 3 (PRO3), is a 26 kDa neutral serine protease found to be overexpressed in CML cells of patients in accelerated phase or blast phase (BP). 47 PR1 is a nonapeptide derived from PRO3 (Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val) presented through HLA-A2.1 molecules.
47 PR1-specific cytotoxic T lymphocytes have been found in most patients with CML who have responded to IFN-a or allogeneic SCT, but not in nonresponding patients. 47, 48 Of the 10 patients with CML who received the PR1 vaccine in a phase I study, 1 had a CCyR and 3 had improvement in the percentage of Ph-positive bone marrow metaphases. 49 Ongoing studies will address the efficacy of PR1 vaccine to eradicate minimal residual disease in CML.
Because the expression of the BCR-ABL1 kinase is restricted to CML cells, an obvious approach to develop CML vaccines is to use peptide sequences spanning the BCR-ABL1 break point. The joining region of the p210 BCR-ABL chimeric protein juxtaposes unique amino-acid sequences of both ABL1 and BCR that are distinctly expressed by CML cells. Two alternative chimeric p210 BCR-ABL1 proteins, comprising either a b3a2 or a b2a2 junction, account for 495% of the fusion peptides found in clinical samples. Several BCR-ABL1 junction-spanning sequences have been shown to induce HLA class II-restricted T cell-mediated cytotoxicity from lymphocytes of patients with CML. 50 Recently, 16 patients expressing a b3a2 p210
BCR-ABL1
fusion transcript with stable residual disease after therapy with imatinib or IFN-a were vaccinated with a peptide derived from p210-b3a2 (CMLVAX100). 51 Five of nine patients on imatinib with persistent Ph-positive metaphases had a CCyR postvaccination, and in three BCR-ABL1 transcripts became undetectable. Among the patients who had received IFN-a, two achieved a CCyR and three improved the percentage of Phpositive metaphases. These studies suggest that the CMLVAX100 vaccine may aid in the management of minimal residual disease.
Other vaccination approaches that have shown promising results for the management of minimal residual disease involved the employment of cell lysates containing heat shock proteins (HSP)-peptide complexes obtained from autologous CML cells (HSP70PC vaccine), 52 vaccines derived from heteroclinic peptides derived from the Wilms' tumor 1 (WT-1) transcription factor, which is overexpressed in solid tumors and leukemia 53 and the K562/GM-CSF (GVAX) vaccine, a tumor vaccine derived from a CML cell line that expresses several CMLassociated antigens and has been genetically engineered to produce granulocyte-macrophage colony-stimulating factor (GM-CSF). 54 A potential drawback of vaccines directed toward a unique epitope is the possibility that the malignant clone downregulates or mutates the target epitope, thus causing 'immune escape'. A potential way to overcome this drawback is the simultaneous use of several vaccines. An ongoing study evaluating the safety and activity of combining the PR1 and WT1 peptide vaccines has shown the feasibility and efficacy of such strategy. 55 Targeting BCR-ABL kinase downstream pathways
HSP90 chaperone complex
The heat shock protein HSP90 chaperones a wide array of protein kinases found activated in CML, such as p210 BCR-ABL1 , mitogen-activated protein/extracellular signal-regulated kinase (MEK) and AKT. Therefore, inhibiting HSP90 could simultaneously disable several key pathways in CML pathogenesis. The benzoquinone ansamycin antibiotic 17-allylamino-17-demethoxygeldanamycin (17-AAG) binds avidly to and disrupt the function of HSP90, resulting in the depletion of multiple 'client' proteins through proteasome-mediated degradation. 56 Treatment of HL-60/BCR-ABL1 and K562 cells with 17-AAG shifts the binding of BCR-ABL protein kinase from HSP90 toward HSP70, resulting in its proteasomal degradation and downregulation of c-RAF and AKT kinase activity. 57 Notably, 17-AAG remains active in the presence of the highly imatinib-resistant mutant isoforms of BCR-ABL1 T315I and E255K, 56 and has proven highly active in combination with the histone deacetylase inhibitor LBH589 against human BP CML cell. 58 Initial phase I studies in which 17-AAG (KOS-953, tanespimycin) was administered intravenously to patients with solid tumors, established reversible, grade 3 hepatic toxicity as dose-limiting at 56 mg m À2 . 59 Results of ongoing studies combining 17-AAG with imatinib are eagerly anticipated. Perhaps more intriguing is the activity of KOS-1022 (17-dimethylaminoethylamino-17-demethoxygeldanamycin), another geldanamycin derivative with 3-5 times higher potency compared to 17-AAG, that has shown good tolerance and biologic activity in a phase I study including 12 patients with refractory acute myeloid leukemia and 1 with CML.
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PI3K/AKT/mTOR pathway
Phosphorylation of the Tyr177 residue in BCR-ABL1 is necessary for the binding of GRB2, 61 ,62 which in turn, binds the scaffolding adapter protein GAB2. As a consequence, GAB2 is phosphorylated and binds to phosphatidylinositol 3-kinase (PI3K), thus activating the PI3K/AKT pathway that promote antiapoptotic and leukemogenic signals, 1, 63 thus making the PI3K/AKT pathway a target for drug development in CML.
The serine/threonine kinase mammalian target of rapamycin (mTOR) is downstream of PI3K and AKT that regulates cell growth and proliferation. 64 Rapamycin is a potent immunosuppressive agent which, upon binding to its main intracellular receptor FKBP, binds with high-affinity mTOR. Rapamycin enhanced the inhibitory effect of imatinib on BCR-ABL1-transformed cells, including both unmutated and imatinibresistant mutant isoforms, except for T315I, via G 1 -phase cell cycle arrest and inhibition of vascular endothelial growth factor production. 65, 66 Of note, imatinib therapy can induce a compensatory AKT/mTOR activation that results in persistence of BCR-ABL1-positive cells in patients with CML. 67 Treatment with mTOR inhibitors may therefore be particularly effective in imatinib-sensitive patients. Other mTOR inhibitors such as everolimus (RAD001) or temsirolimus (CCI779) are currently under investigation in clinical trials for patients with CML with suboptimal response to imatinib.
RAS/RAF pathway
RAS signaling, a crucial for cellular growth and proliferation of leukemic cells, is part of the BCR-ABL1 downstream signaling network. RAS activation occurs at the inner plasma membrane 68 and is accomplished through a post-translational prenylation Experimental non-ATP-competitive therapies for CML A Quintás-Cardama process by which a 15-carbon isoprenyl (farnesyl) moiety is attached to the C-terminal cysteine residue by the enzyme farnesyltransferase (Ftase) and to a lesser extent by geranylgeranyl-protein transferases. 69 Ftase inhibitors (FTIs) inhibit farnesylation of a variety of proteins including RAS. 70 Although FTIs have shown only modest activity in CML as single agents, 71 the combination of imatinib with either tipifarnib 72 or lonafarnib 73 demonstrated significant clinical activity in phase I studies in imatinib-resistant CP CML, including in T315I-carrying patients. 72 A combination study of dasatinib and the FTI BMS214662, with 68-fold higher killing potency against quiescent (IC 50 0.7 mM) than proliferating (IC 50 47.5 mM) K562 cells, 74 is underway. Upon activation of RAS, RAF-1 is recruited from the cytosol to the membrane where it is phosphorylated by SRC and other kinases, enabling RAF-1 to activate the MEK/mitogen-activated protein kinase (MAPK) pathway. Sorafenib (BAY 43-9006), an orally bioavailable potent inhibitor of RAF-1, has been shown to potently induce apoptosis in Ba/F3 cells expressing T315I and this activity was associated with rapid and pronounced inhibition of STAT5 phosphorylation. 75 A phase II study is evaluating the activity of sorafenib in patients with imatinibresistant CP CML.
MEK/MAPK pathway
The MEK/MAPK pathway is an important regulator of apoptosis and survival in CML cells through the serine/threonine kinases JNK (c-Jun-activated kinase), p42/44 MAPK (ERK, extracellular signal-regulated kinase) and p38 MAPK. Pharmacological disruption of this pathway with PD98059 has been shown to result in apoptosis of BCR-ABL1-positive cells. 76 Several inhibitors of the enzymes involved in the activation of MAPK kinases MEK1/2 such as PD184352 and U0126 have been shown to induce marked apoptosis in BCR-ABL1-positive imatinib-resistant cells when combined with imatinib. 77 
RAC guanosine triphosphatase inhibitors
The guanosine triphosphatases (GTPases) are RAS-like proteins that oscillate between inactive, guanosine diphosphate (GDP)-bound and active, GTP-bound states and integrate multiple signals from growth factor, chemokine and adhesion receptors to regulate multiple cellular functions (Figure 2) . 78, 79 The RAC subfamily encompass RAC1, RAC2 and RAC3, which regulate engraftment of hematopoietic stem cells (HSC), cell cycle progression and HSC retention within the hematopoietic milieu. BCR-ABL1 kinase binds to and activates RAC GTPases, which can be found hyperactivated in cells from patients with CML. 79 In a murine model of p210
BCR-ABL1 -induced myeloproliferative disorder, gene targeting of RAC1 and RAC2 remarkably delayed or avoided disease development and this was paralleled by abrogation of phosphorylation of the BCR-ABL downstream signaling molecules CrKL, ERK, JNK and p38. 79 These results suggest that BCR-ABL1 kinase signaling is highly dependent on RAC GTPases, which renders the latter as unique molecular targets for CML therapy. Treatment with increasing concentrations of the specific highly soluble and membrane permeable RAC1/RAC2 small-molecule inhibitor NSC23766 78 inhibited remarkably the growth of primary bone marrow cells from patients with BP CML as well as Ba/F3 cells expressing the pan-TKI insensitive mutant BCR-ABL1 T315I, 79 further supporting the notion that GTPases may be amenable to pharmacological intervention in human CML. Notably, chronic therapy with NSC23766 was relatively nontoxic and prolonged survival when administered to mice with p210
BCR-ABL1
-induced leukemia. 79 
Histone deacetylase inhibitors
A wide array of modifications occurring at the N-terminal 'tails' of histones, including acetylation, methylation, phosphorylation and glycosylation play a key role in gene transcription. 80 Hystone deacetylases (HDACs) remove acetyl groups at the N terminus of histone proteins, resulting in chromatin condensation and transcriptional repression. It has been recently reported that treatment with HDAC inhibitors such as SAHA, LAQ824 and panobinostat (formerly LBH589) results in depletion of BCR-ABL1, induces apoptosis and sensitizes human leukemia cells to imatinib-induced apoptosis. This activity is believed to be mediated through inhibition of HDAC6 and acetylation of HSP90 that results in proteasomal degradation of HSP90 client proteins such as BCR-ABL1, c-RAF and AKT. 58, 81, 82 Co-treatment of the BCR-ABL1-positive human K562 and LAMA-84 cells with the intravenously bioavailable cinnamic hydroxamic acid analogue HDAC inhibitor panobinostat and the second-generation TKI nilotinib resulted in synergistic apoptotic activity, decreased phosphorylation of p-STAT5 and p-ERK1/2 and increased levels of p27 and Bim. 83 Most importantly, this combination induced apoptosis of BCR-ABL1 T315I-positive primary CML cells, supporting its potential for the treatment of TKI-resistant CML. 83 Other HDAC inhibitors such as depsipeptide (FK228) have shown a preferential proapoptotic effect against BCR-ABL1-positive cells in vitro and ex vivo. 84 Ongoing clinical studies in patients with refractory CML will clarify the activity of panobinostat in patients after failure of TKI therapy.
PP2A activators
Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that is composed of a catalytic subunit (C), a structural Experimental non-ATP-competitive therapies for CML A Quintás-Cardama subunit (A) and a variable regulatory subunit (B). Three different families of PP2A-B subunits have been described thus far. PP2A acts as a tumor suppressor in CML by antagonizing BCR-ABL1 and its inactivation is linked to disease progression. 85 BCR-ABL1 inhibits PP2A by post-transcriptional upregulation of SET, a phosphoprotein that functions as a physiological inhibitor of PP2A. 85 Further support of the role of PP2A in CML progression is provided by the fact that the expression of active PP2A recruits and activates the Src homology region 2 domain-containing protein tyrosine phosphatase 1 (SHP1), which catalyzes BCR-ABL1 dephosphorylation, leading to BCR-ABL1 downregulation through proteosomal degradation. 85 Thus, downregulation or inhibition of SET or the activation of PP2A are potential strategies for the treatment of CML. In fact, the silencing of SET by siRNA results in reduced expression of BCR-ABL1. 85 In addition, treatment of BCR-ABL1-positive cells with forskolin, a pharmacological activator of PP2A, led to reduced expression of BCR-ABL. 85 Another potential PP2A activator is FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride), an immunosuppressive drug that is a metabolite of the ascomycete Isaria sinclairii.
86 FTY720 has been shown to be efficacious and safe in phase I and II trials as chronic immunosuppressive therapy administered orally. 87 In vitro, FTY720 at 500 nM-2.5 mM induced caspase-dependent apoptosis and impaired clonogenic potential of imatinib and dasatinibsensitive and -resistant BCR-ABL1 myeloid and lymphoid cell lines (K562, 32D-p210 BCR-ABL1 , 32D-p210(T315I) BCR-ABL1 and BaF3-p190 BCR-ABL1 ) and of primary bone marrow cells from patients with CML-BP and BCR-ABL1-positive B-ALL. 88 Treatment with FTY720 (10 mg kg À1 per day) suppressed leukemogenesis in severe combined immunodeficient mice transplanted with myeloid or lymphoid progenitor cells transformed with p210 BCR-ABL1 or p190 BCR-ABL1 , respectively. More importantly, 80 and 90% of p210 and p190 mice, respectively were in molecular remission after 11 weeks of therapy with FTY720, as well as 50% of mice transplanted with progenitors expressing the multiresistant T315I p210 BCR-ABL1 mutant. 88 FTY720 acts as a superagonist of the sphingosine-1-phosphate-1 receptor 87 and its antileukemic activity is mediated by dephosphorylation of AKT and activation of PP2A phosphatase, which inhibits the activity and expression of wild-type and mutant p210 and p190 BCR-ABL1 oncoproteins. 88 These preclinical observations support the use of FTY720 as a therapeutic approach for the treatment of CML in BP as well as BCR-ABL1-positive B-ALL, including those cases expressing the highly resistant T315I mutant.
BCR-ABL1 kinase increases the expression of the PP2A-B subunit isoforms B55a, B56a and B56d. 89 Although the functional role of each subunit is not well understood, it is likely that varying levels of these subunits may alter the composition and specificity of PP2A. 89 Given the importance of functional inactivation of PP2A in CML pathogenesis, the elucidation of the role of each regulatory subunit may aid in the development of new targets against which to develop novel therapies for CML.
Other experimental approaches to CML therapy
BCR-ABL nuclear entrapment
The BCR-ABL1 oncoprotein locates exclusively to the cytoplasm of CML cells. 90 However BCR-ABL1 retains three nuclear localization signals (NLS) in the ABL1 moiety and a nuclear export sequence (NES). 91 Inhibition of the kinase activity of BCR-ABL1 by imatinib partially resumes the import of BCR-ABL1 to the nucleus, where subsequent reactivation of its catalytic activity after imatinib washout activates apoptosis. 91 This effect can be further exacerbated by the sequential addition of leptomycin, which blocks nuclear BCR-ABL1 export through inactivation of the NES-receptor CRM1/exportin-1. 91 In K562 cells, the combination of leptomycin B with imatinib results in the nuclear sequestration of 20-25% of the BCR-ABL1 protein content, which leads to irreversible cell death via caspase activation. 91 Similar results have been observed on primary bone marrow CML progenitors. 92 However, the clinical application of this innovative strategy to target BCR-ABL1-positive leukemia may be limited by the neuronal and gastrointestinal toxicity associated with leptomycin B. Development of new inhibitors of BCR-ABL1 nuclear export with more acceptable toxicity profiles must be pursued and tested in combination with potent second-generation ABL1 kinase inhibitors (that is, nilotinib, dasatinib and bosutinib).
DNA repair inhibitors
Genome surveillance is impaired in CML cells due to downregulation of BRCA1, the substrate of the ataxia telangiectasia mutated nuclear protein kinase. 93 As a consequence, CML cells are defective in repair of double-strand breaks by the error-free mechanism of homologous recombination (HR) and are predisposed to accumulate genetic lesions. Likely, cells defective in a particular DNA repair pathway will be hyperdependent on an alternative one. When genetic instability is the result of BRCA1 deficiency, inhibition of the DNA repair enzyme poly(ADPribose) polymerase-1 (PARP1) could be used as a means to induce lesions whose repair depends upon BRCA1 activity. As the BRCA1-dependent mechanisms of repair are faulty, alternative error-prone mechanisms act, resulting in chromosome abnormalities that compromise the cell viability, a strategy known as 'synthetic lethality'. Several BRCA-deficient cell types have been shown to have a profound sensitivity to the potent and selective small-molecule PARP1 and PARP2 inhibitors KU0058684 (IC 50 3.2 nM) and KU0058948 (IC 50 3.4 nM), resulting in cell cycle arrest, chromosome instability and cell death. 94 The sensitivity of cells deficient in proteins involved in HR to PARP inhibition suggests that treatment with PARP1 inhibitors may be a useful therapeutic strategy in malignancies which, like CML, exhibit low BRCA1 levels.
Closing remarks
Ample clinical experience accumulated to date suggest that the standard therapeutic paradigm of small-molecule ATP-competitive BCR-ABL1 kinase inhibition (for example, imatinib, nilotinib and dasatinib) is unlikely to result in cure of CML. Data obtained from the International Randomized Study of Interferon trial suggests that most patients receiving imatinib therapy achieve significant degrees of response that translate into high progression-free and overall survival rates. 5 Notably, the annual rates of disease progression appear to decrease among those patients with successful response to this TKI. However, after 5 years of follow-up, only two-thirds of the patients initially started on imatinib are currently receiving therapy with this TKI due to inadequate response and/or poor tolerance. 5 It is therefore evident that the CML armamentarium needs to be expanded with novel therapies to overcome the major hurdles associated with ATP-competitive TKI therapy such as poor response rates in advanced-phase CML, low activity against quiescent CML stem cells and development of resistance due to kinase domain mutations 95 and other BCR-ABL1 kinase-independent mechanisms. Although most therapies herein described are yet to be fully characterized and their therapeutic potential is far from being completely realized, they represent promising options that warrant clinical investigation in patients with CML resistant to standard TKI therapy. A more profound knowledge of the pathogenesis of CML, particularly of the mechanisms of resistance and progression to BP, will undoubtedly facilitate the development of novel therapeutic approaches that will further improve the outcome of patients with this disorder.
